← Leaderboards
Brendan Andrew Frett
Synactix Pharmaceuticals, Inc.
$1,221,643
Attributed
$1,591,614
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $300K · FY2015–23$500K$375K$250K$125K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$1,591,614 · 3
By mechanism
P20$951,664 · 1
R41$639,950 · 2
Top collaborators
- Hong Yu Li2 shared
- Monica L Guzman1 shared
- Hong-Yu Li1 shared
Most similar at Synactix Pharmaceuticals, Inc.
Same institution · by research overlap
- Hong Yu Li$392,875
Others in their field
Top investigators on “Plasma”
- David Heimbrook · Leidos Biomedical Research, Inc.$170,532,526
- Barton F Haynes · Duke University$119,611,088
- Paul S. Aisen · Cognition Therapeutics, Inc.$110,079,727
- Tatiana M. Foroud · Indiana Univ-Purdue Univ At Indianapolis$93,527,289
- Walter C. Willett · Harvard University (Sch Of Public Hlth)$85,429,770
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$78,577,996
Research focus
PlasmaDoseDesignPropertyMonitorMediatingPathway InteractionsSignal TransductionCellsToxic EffectSmall MoleculePharmaceutical PreparationsAnimalsBiological AvailabilityBiochemicalAcuteDeteriorationExposure ToCenters Of Research ExcellenceCytokineCell InjuryComplicationChestCombat
Grant awards (7)
Concurrent TNF-alpha and TGF-beta Impairment to Limit Radiotherapy-Induced Pulmonary Fibrosis$136,800
P20 · FY2023 · GM · contact PI
Concurrent TNF-alpha and TGF-beta Impairment to Limit Radiotherapy-Induced Pulmonary Fibrosis$267,664
P20 · FY2022 · GM · contact PI
Concurrent TNF-alpha and TGF-beta Impairment to Limit Radiotherapy-Induced Pulmonary Fibrosis$273,600
P20 · FY2021 · GM · contact PI
Concurrent TNF-alpha and TGF-beta Impairment to Limit Radiotherapy-Induced Pulmonary Fibrosis$273,600
P20 · FY2020 · GM · contact PI
Preclinical studies of Selective and Orally Bioavailable Aurora B Inhibitors for the Treatment of AML$299,975
R41 · FY2018 · CA
Synactix Pharmaceuticals I-Corps Application$40,000
R41 · FY2016 · CA
Pre-IND Study of Pz-1, a dual pan-RET/VEGFR2 inhibitor for the Treatment of RET-driven Disease$299,975
R41 · FY2015 · CA